Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate‐P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy
Authors:
- for the Humate‐P Study GroupFGfor the Humate‐P Study Group
- 21 November 2003
- journal article
- clinical trial
- Published by Wiley in Haemophilia
- Vol. 9 (6) , 688-695
Abstract
Summary. This prospective, open‐label, non‐randomized study evaluated the safety and efficacy of factor VIII (FVIII)/von Willebrand Factor (VWF) concentrate (Humate‐P®) using treatment regimens based on VWF:ristocetin cofactor (VWF:RCo) activity in patients with von Willebrand Disease (VWD) in (i) urgent bleeding episodes, or (ii) in patients undergoing urgent and necessary surgery. This article summarizes the results of treatment for the 33 patients with 53 urgent bleeding events. The median loading dose of FVIII/VWF concentrate was 67.0 international units per kilogram (IU kg−1) VWF:RCo (range 25.7–143.2 IU kg−1), and the median daily maintenance dose per infusion was 74.0 IU kg−1 (range 16.4–182.9 IU kg−1) for a median duration of 2 days (range 1–34 days). The overall efficacy (achievement of haemostasis) of FVIII/VWF concentrate was rated as excellent/good for 98% of the urgent bleeding events. No unexpected treatment‐related adverse events or serious drug‐related adverse events (AEs) were observed. This study supports the safety and efficacy of Humate‐P® administered in doses calculated in VWF:RCo units for the treatment of urgent bleeding episodes in patients with VWD.Keywords
This publication has 22 references indexed in Scilit:
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTORAnnual Review of Biochemistry, 1998
- Experience with Haemate P in von Willebrand’s Disease in AdultsPathophysiology of Haemostasis and Thrombosis, 1994
- Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technologyAnnals of Hematology, 1991
- Correction of prolonged bleeding time in von Willebrand's disease with Humate‐PTransfusion, 1990
- Absence of Anti-Human Immunodeficiency Virus Types 1 and 2 Seroconversion after the Treatment of Hemophilia A or von Willebrand's Disease with Pasteurized Factor VIII ConcentrateNew England Journal of Medicine, 1989
- Use of a High‐Purity Factor VIII Concentrate (Hemate P) in von Willebrand's Disease1Vox Sanguinis, 1989
- Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.Journal of Clinical Investigation, 1988
- The effect of thrombin on the complex between factor VIII and von Willebrand factorEuropean Journal of Biochemistry, 1987
- Factor VIII binds to von Willebrand factor via its Mr-80000 light chainEuropean Journal of Biochemistry, 1987